Navigation Links
Stonegate Report About Unigene Laboratories Inc.
Date:3/13/2008

ZURICH, Switzerland and FAIRFIELD, New Jersey, March 13 /PRNewswire-FirstCall/ -- "The new Stonegate Report about Unigene confirms that we are uniquely positioned as the only biopharma company that manufactures peptides by recombinant techniques, while also having oral and nasal delivery systems to administer the peptides. Since the launch of "Fortical" in 2005 with partner Upsher-Smith Laboratories, "Fortical" has captured a near dominant 49% market share of the U.S. nasal calcitonin market that is estimated to be in the $200 million range."

Stonegate Securities, Inc. Unigene Laboratories Inc. (WKN 875852, ISIN US9047531002, UUL, OTCBB: UGNE)

Price $1.80

52-Week Range $1.50 - $2.70

Market Capitalization 157,952,000

Enterprise Value 166,734,000

Primary Shares Outstanding 87,751,000

Float 83,190,000

Insider Ownership 5%

Institutional Ownership 15%

Daily Volume (3-Month Avg.) 94,000

Industry Biopharmaceuticals

Website http://www.unigene.com

Corporate Headquarters Fairfield, NJ

Company Description

Unigene is a biopharmaceutical company that focuses on the research, production and delivery of therapeutic peptides. Its initial focus is on salmon calcitonin (sCT) and other peptides for the treatment of chronic bone and joint disorders. Unigene received FDA approval for Fortical(R), a sCT-based product that addresses the osteoporosis market, in 2005. Upsher-Smith Laboratories licensed the rights to Fortical(R). In addition, Unigene has developed a patented manufacturing process for the efficient production of peptides and patented technologies for the oral and nasal delivery of peptides. The Company has also licensed the worldwide rights
'/>"/>

SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Helix BioPharma reports Q2 2008 highlights, financial results
5. Oncothyreon reports full year and fourth quarter 2007 financial results
6. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... N.J., July 10 Senesco Technologies , Inc. ... announced that, on July 9, 2009, the Company entered into a ... sale of (i) up to 1,111,111 shares of its common stock ... to purchase an aggregate of up to 1,000,000 shares of common ...
... of Energy,s Lawrence Berkeley National Laboratory and the University ... fabricate efficient solar cells from low-cost and flexible materials. ... of nanoscale pillars, each a single crystal, with dimensions ... take advantage of abundant solar energy we have to ...
... July 9 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today announced that the U.S. ... of the Company,s proposed development plan for SparVax(TM), PharmAthene,s ... , In response to amendments to the request ...
Cached Biology Technology:Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 3Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 4Nanopillars promise cheap, efficient, flexible solar cells 2Nanopillars promise cheap, efficient, flexible solar cells 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 2PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 4
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... the Max Planck Institute for Medical Research in Heidelberg, ... photosynthesis, the process by which the Earth first gained ... which is therefore crucial for all higher forms of ... first direct visualization of a crucial event in the ... protein complex, photosystem II, splits water into hydrogen and ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2
... available in Spanish . Learning more ... used by U.S. Department of Agriculture (USDA) scientists to identify ... bed bugs over the last decade has caused problems in ... and even places of work. The small, blood-feeding insects are ...
... have found that one of the most aggressive invasive ant ... appears to have met its match in the Asian needle ... ant is successfully displacing Argentine ants in an urban environment, ... sting may be the next invasive species to see ...
... MDIf you have an overactive bladder or incontinence, help could be ... FASEB Journal , shows that the epithelium, a ... is able to sense how full the bladder is through the ... bladder becomes full, the cells in the epithelium stretch and become ...
Cached Biology News:Studying bed bug actions for new management tactics 2Researchers find Asian needle ants displacing other aggressive invaders 2Got to go? Harvard scientists figure out how you know 2
... and PowerPac 3000 system, 220-240 V, is used ... 50 cm vertical slab gel format. The system ... is capable of separating nucleic acids with single ... (IPC) assembly (IPC and bonded inner glass plate, ...
... Plus overlay agarose is used for ... IPG strips in place in PROTEAN ... is incorporated to allow monitoring of ... of 0.75% agarose in 1x Tris, ...
... The PowerPac HV high-voltage power supply, with ... increased output of 5,000 V, 500 mA, and ... monitor gel temperature between 0 and 90 degrees ... wireless data transfer. Power cord and instructions are ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
Biology Products: